Duchenne Muscular Dystrophy Market Growth Trajectory Through 2024-2033

The Duchenne Muscular Dystrophy Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Duchenne Muscular Dystrophy Market:
https://www.thebusinessresearchcompany.com/report/duchenne-muscular-dystrophy-global-market-report

According to The Business Research Company’s Duchenne Muscular Dystrophy Global Market Report 2024, The duchenne muscular dystrophy market size has grown strongly in recent years. It will grow from $1.07 billion in 2023 to $1.17 billion in 2024 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to genetic understanding and diagnostic advances, clinical trial progress, patient advocacy and awareness, orphan drug designation and incentives, collaborative research initiatives.

The duchenne muscular dystrophy market size is expected to see strong growth in the next few years. It will grow to $1.61 billion in 2028 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to emerging gene therapies, precision medicine approaches, expanded access to therapies, long-term follow-up studies, regulatory advancements. Major trends in the forecast period include integration of digital health technologies, technological advancements in therapeutics, gene therapies and genetic medicines, regulatory support for orphan drugs, precision medicine approaches.

The increasing prevalence of chronic diseases is expected to propel the growth of the Duchenne muscular dystrophy market in the future. A chronic disease is a health issue or condition with long-lasting symptoms lasting for at least a year. The Duchenne muscular dystrophy contributes to the prevalence of chronic diseases by addressing the specific therapeutic needs of individuals with this genetic disorder, highlighting the broader significance of personalized medicine in managing and potentially mitigating the impact of chronic conditions. For instance, in January 2023, according to the National Institutes of Health (NIH), a U.S. government agency that conducts and supports biomedical and health-related research, the study projects a substantial rise in the prevalence of chronic diseases among the working-age population in the United States, with an estimated 99.5% increase in adults aged 50 years and older with at least one chronic disease from 2020 to 2035. Additionally, the prevalence of multimorbidity is expected to surge by 110.5% from 2020 to 2050, highlighting the growing health challenges faced by the working population. Therefore, the increasing prevalence of chronic diseases is driving the growth of the Duchenne muscular dystrophy market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=10368&type=smp

The duchenne muscular dystrophy market covered in this report is segmented –
1) By Therapy: Mutation Suppression, Exon Skipping Approach
2) By Therapeutic Class: Molecular Based Therapies, Steroid Therapy
3) By Route of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Major companies operating in the Duchenne muscular dystrophy market are focusing on product innovations, such as the first gene therapy to treat Duchenne Muscular Dystrophy. This therapy involves introducing functional copies of the dystrophin gene into affected individuals to address the genetic mutation responsible for the progressive muscle degeneration characteristic of the disease. For instance, in June 2023, Sarepta Therapeutics, a US-based biopharmaceutical company that develops RNA-based treatments for rare and infectious diseases, announced FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy. This groundbreaking one-time treatment utilizes advanced gene therapy technology to address the genetic cause of the disease. Its significance lies in revolutionizing DMD treatment, representing a breakthrough from traditional supportive care approaches, potentially enhancing patients’ quality of life and life expectancy while showcasing the transformative potential of gene therapy in addressing rare diseases.

The duchenne muscular dystrophy market report table of contents includes:
1. Executive Summary
2. Duchenne Muscular Dystrophy Market Characteristics
3. Duchenne Muscular Dystrophy Market Trends And Strategies
4. Duchenne Muscular Dystrophy Market – Macro Economic Scenario
5. Global Duchenne Muscular Dystrophy Market Size and Growth
….
31. Global Duchenne Muscular Dystrophy Market Competitive Benchmarking
32. Global Duchenne Muscular Dystrophy Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Duchenne Muscular Dystrophy Market
34. Duchenne Muscular Dystrophy Market Future Outlook and Potential Analysis
35. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model